Cogent Biosciences (COGT) is the lead sponsor of 5 active clinical trials listed on ClinicalTrials.gov[4], including 1 Phase 3[1], 3 Phase 2[2], 2 Phase 1[3].
Trial NCT05208047[5] evaluates CGT9486 plus sunitinib in Advanced Gastrointestinal Stromal Tumors with a target enrollment of 442 participants.
COGT has 2 Form 4 insider filings recorded at the SEC in the past 30 days[6].